Index. Adv Biochem Eng Biotechnol (2013) 130: DOI: / Ó Springer-Verlag Berlin Heidelberg 2013

Transcription

1 Adv Biochem Eng Biotechnol (2013) 130: DOI: / Ó Springer-Verlag Berlin Heidelberg 2013 Index A Acute lung injury (ALI), 105, 113 endotoxin-induced, 45 Acute respiratory distress syndrome (ARDS), 113 Adhesion, 175, 218, 278 molecules, 4, 11, 23, 135, 201, 223, 279 proteins, 223 receptors, 23 Adipocytes, 269 Adipose-derived stromal cell (ADSC), 56, 89, 93, 278 Adipose stromal cells (ASC), 56, 163, 278 Adipose tissue, 110, 267 Adult progenitor cells, 39, 43 Advanced therapy medicinal products (ATMP), 287 Alloderm (ADM), 50 Allodynia, Allogeneic hematopoietic stem cell transplantation (allo-hsct), 131, 132 Allotransplantation, 55 Alveolar bone proper-derived stem cell, 89 Amniotic fluid, 136, 267, 272 Anaphylatoxin C3a, 26 Angiogenesis, 240 Angiogenic factors, 4 Antiapoptotic factors, 4, 111, 240 Anti-inflammatory, 163 Apoptosis, 6, 31, 48, 59, 75, , 215, 242 Asthma, 40, 119 Autologous chondrocyte transplantation (ACT), 78 Azathioprine, 49 B Bifrons, 245 Bioactive factors, 163 Bioartificial liver devices (BAL), 6 Bone marrow, 26, 109, 115, 132, 163, 276 cells, harvesting, 75 mononuclear cells (BMNCs), 47 stromal cells, 78, 89, 147 stromal stem cells (BMSSCs), 92, 163 Bone morphogenic proteins (BMP), 71, 76, 79, 270 Bone regeneration, 69 Bortezomib, 244 Bronchial asthma, 119 Burns, 55 C C-reactive protein (CRP), 47 Calcium sulphate, 72 Carboxyesterase, 244 Carcinoma-associated fibroblasts (CAF), 228 Cartilage regeneration/repair, 2, 69, 78 CD44, 23, 91, 280 CD73, 91, 98, 108, 111, 137, 176, 234, 268, 280 CD90, 91, 97, 108, 111, 137, 176, 234, 268, 280 CD105 (endogline), 91, 97, 108, 111, 137, 176, 234, 268, 280 CD146, 268 CD166, 268 CD271, 268 Cell reprogramming, 44 Cell therapy, 39, 41

2 306 Index Cell transplantation, 1 Cell-based therapies (CBTs), 163 Chemokines, 5, 27, 79, 136, 163, 244 Chondroblasts, 269 Chronic obstructive pulmonary disease (COPD), 40, 46, 49, 105, 115 Clinical Trials Facilitation Group (CTFG), 295 Collagen, 4, 21, 49, 93, 96, 118, 182, 186, 221, 237 Colony-forming unit-fibroblast (CFU-F), 26, 59, 107 Composites, 72 Connective tissue injuries, 2 Cord blood, 267 Crohn s disease, 5 CX3CL1, 244 CXCR4, 23 Cyclosporine, 4, 49 Cystic fibrosis (CF), 105, 115 transmembrane conductance regulator (CFTR), 116 Cytokines, 4, 163, 214 Cytosine deaminase, 244 Cytoskeleton, 4 D Danger/stress responses, 163 Dendritic cells (DCs), 199, 201 cytoskeleton rearrangement, 199 differentiation, 199 maturation, 199 phenotype, 199 tolerogenic, 199 Dental follicle stem cells (DFSCs), 89, 94 Dental pulp stem cells (DPSCs), 89, 93 Dentine matrix protein 1 (DMP1), 92 Dentine sialophosphoprotein (DSPP), 92 Dexamethasone, 76 Dickkopf-related protein-1 (DKK-1), 74, 77, 242 DNA methyltransferase inhibitors, 8 E Endothelial cells, 227, 232 Endothelial nitric oxide synthase (enos), 48, 113 Endothelial progenitor cells (EPCs), 47 Endothelial to mesenchymal transition (EndMT), 231 Endothelin binding receptor (ETBR), 228 European Directorate for the Quality of Medicines and HealthCare (EDQM), 293 Ewing sarcomas, 30 Extracellular matrix (ECM) proteins, 97, 169, 177, 183, 213, 221 F Fat grafting, 55 Fibronectins, 4, 182, 221, 237 Fluorescence-assisted cell sorting (FACS), 58 5-Fluorocytosine (5-FC), 244 G Galectin-1, 137 Ganciclovir, 30 Gene therapy medicinal products, 289 Gingival stem cells, 89, 97 Good manufacturing practice (GMP), 295 Graft-versus-host disease (GvHD), 4, 131, 133, 275 Graft-versus-leukemia (GvL) reaction, 133 Growth factors, 74, 214 GTPase, 11 Guideline on Human Cell-Based Medicinal Products, 296 H Hematopoietic disorders, 131 Hematopoietic stem cells (HSC), 43, 132, 163, 273 transplantation (HSCT), 199 Hemoxygenase-1 (HO-1), 201 Hepatocyte growth factor (HGF), 137, 214 Histone deacetylase inhibitors, 8 Homing, 19 Human embryonic stem cells (ESCs), 7, 42 Human ipsc-derived MSCs (hipsc-mscs), 9 Human leukocyte antigens, 137, 269 HLA-II, 269 HLA-G, 137 Hurler syndrome, 27 Hydroxyapatite, 72 Hypopharyngeal carcinoma, 50 I Idiopathic pulmonary arterial hypertension (IPAH), 47, 49

3 Index 307 Idiopathic pulmonary fibrosis (IPF), 105, Immune response, 163 Immune synapse, 199 Immunodeficiencies, 131 Immunomodulation, 163 Immunosuppression, 131, 163 Indoleamine-2,3-dioxygenase (IDO), 11, 32, 137, 174, 176, 201 Induced pluripotent stem cells (ips), 1, 39, 166, 267, 271 Inflammation, 27 Inflammatory bowel diseases (IBD), 1, 5 Instant blood-mediated inflammatory reaction (IBMIR), 26 Integrins, 4, 23, 222 Interferons (IFNs), 163 IFN-c, 11, 215 Interleukins (ILs), 5, 163, 237 IL-1b, 215 IL-2, 5, 150, 218, 244 IL-6, 32, 48, 74, 137, 189, 201, 205, 216, 228, 236 IL-8, 216, 228, 238 IL-10, 6, 23, 32, 114, 137, 189, 202, 216 IL-12, 5, 30, 137, 203, 215, 226, 244 Intravenous injection, 19 Irradiation, 27 Ischemia, 27 J Janus Bifrons, 245 L LacZ (B16-LacZ), 30 Laminins, 223 Leukemia, 4, 41, 131, 137, 183, 187 inhibitory factor (LIF), 137, 174, 239 Lewis lung carcinoma (LLC), 30 Lipofilling, 55 Lipopolysaccharide (LPS), 202 Liver, diseases, 1 regeneration, 6 Long-bone defects, 77 Lung cancer, 40 Lung disease, 105 chronic, 105, 115 Lung tissue, engineered, 120 Lymphocytes, 225 M Macrophages, 225 Matrix extracellular phosphoglycoprotein (MEPE), 95 Matrix metalloproteinases (MMPs), 4, 25, 213, 219 Mesenchymal stem cells (MSCs), 1, 19, 55, 89, 105 adipose tissue, 277 adult, 267, 275 anti-tumor efficacy, 30 bone marrow, 276 foetal-derived, 272 isolation/tracing, 58 licensing, 199 mediated immunosuppression, 199 multipotent stromal or mesenchymal stem cell, 163 neonatal-derived, 273 placental, 273 therapeutic applications, 267 tumor-engrafted, 30 Mesenchymal stromal cells, 1, 19, 43 clinical grade, 131 Metachromatic leukodystrophy, 27 Methotrexate, 4 Microenvironment, 209 Mitogenic factors, 4 MSC1, pro-inflammatory MSC phenotype, 163 MSC2, anti-inflammatory MSC phenotype, 163 Myeloid-derived suppressor cells (MDSCs), 213, 226 N National Competent Authorities (NCAs), 292 Nestin, 94, 96, 147, 302 Notch 1/2, 94, 199, 206, 232 O Osteoblasts, 21, 71, 91, 94, 97, 107, 136, 147, 174, 219, 269, 271 Osteocalcin, 93, 96 Osteochondral defects, 83 Osteogenic cells, 70, 73, 270, 276 Osteogenic deficiencies, 2 Osteopontin, 93, 96

4 308 Index P Paclitaxel, 31 Patient-specific pluripotent stem cells, 7 Pax-9, 92 Pectoralis major myocutaneous flaps (PMMFs), 50 Periodontal ligament stem cells (PDLSCs), 89, 96 Periodontium, 89 Placenta stem cells, 273 Plasminogen activator inhibitor, 220 Plastic surgery, 55, 56 Platelet-derived growth factor (PDGF), 217 Pluripotent stem cells, 7 induced (ipscs), 44 Processed lipoaspirate (PLA) cells, 278 Pro-inflammatory, 163 Prostaglandins, 23, 32, 114, 137, 174, 199, 201, 239 Proteasome inhibitors, 244 Proteolytic enzymes, 219 Pro-tumorigenic effects, 30 Pulmonary hypertension (PH), 40, 47, 120 Pulmonary vascular disease, 120 R Radiation injury, 55 Radiation-induced lung injury, 48 Rap1, 11 Reactive oxygen species (ROS), 224, 227 Reconstructive surgery, 55 Regulatory framework, 287 Reprogramming, 45 Respiratory diseases, 39 Rosiglitazone, 62 S Scaffolds, 71 Scar repair, 55 Selectins, 23, 27 Serine protease plasmin, 220 Somatic cell nuclear transfer (SCNT), 7 Somatic cell therapy medicinal products, 289 Stanniocalcin-1 (STC1), 224 Stem cells, alveolar bone proper-derived, 97 amniotic fluid, 272 apical papilla (SCAP), 89, 95 banks, 76 cord blood, 274 dental pulp, 89 embryonic (ESCs), 3, 7, 39, 42, 95, 108, 166, 224, 270, 293 gingival, 97 hematopoietic (HSC), 273 human exfoliated deciduous teeth (SHEDs), 89, 95 induced pluripotent (ips), 271 multipotent, 105 periodontal ligament (PDLSCs), 89, 96 placental, 273 Stirred suspension bioreactors (SSBs), 10 STRO-1, 91 97, 111, 278, 302 Stromal derived factor-1 (SDF-1), 217 Stromal vascular fraction (SVF), 56, 59, 277 Suicide genes, 244 Surface markers, 3 T TAT (thrombin-anti-thrombin complex), 26 Tenascin-C, 223 Therapy, 19, 62 Thizolinedione (TZD), 62 Thymidine kinase, 244 Tissue engineered products (TEPs), 288, 289 Tissue engineering, 45, 55, 76, 93, 120, 270 Tissue inhibitor of metalloproteinases (TIMPs), 213, 220 Tissue scaffold, 50 Toll-like receptors, 163 Trachea, bioengineered, 51 Transcription factors, 7 Transforming growth factors (TGF), 9, 74, 79, 95, 137, 174, 201, 215, 217, 302 Transplants/transplantation, 19, 287 Treg cells, 199 Tumor, 29 microenvironment, 214 stroma, 109 Tumor-associated fibroblasts (TAF), 209, 228 Tumor-associated macrophages (TAM), 226 Tumor necrosis factor (TNF), 5, 24, 135, 176, 202, 216, 218 Tumor necrosis factor-related apoptosisinducing ligand (TRAIL), 209, 244

5 Index 309 U Ulcerative colitis, 5 Umbilical cord stem cells (UCSCs), 4, 76, 110, 133 Unrestricted somatic stem cells, 199 Urokinase plasminogen activator (upa), 220 V Vascular cell adhesion molecule (VCAM), 24, 93, 206, 268 Vascular endothelial growth factor (VEGF), 4, 47, 60, 74, 113, 216, 219, 238 W Warburg effect, 223 Wound healing, 55 X Xenografts, 3